Haleon PLC Sponsored ADR (NYSE:HLN) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Haleon has a consensus “Moderate Buy” rating from nine analysts: two rate it a buy, two a strong buy, four a hold and one a sell.
• The company reduced its dividend to $0.0642 per share from $0.1307, while shares recently opened at $9.24—near the lower end of their 12-month range of $8.65 to $11.28.
• Institutional investors made mixed but generally positive moves, with NorthRock Partners increasing its position by 31.5%; hedge funds and other institutions collectively own 6.67% of Haleon.

Shares of Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and two have given a strong buy rating to the company.

Several research analysts have weighed in on HLN shares. Weiss Ratings reiterated a "hold (c)" rating on shares of Haleon in a research note on Tuesday, June 30th. Royal Bank Of Canada restated a "sector perform" rating on shares of Haleon in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Haleon in a report on Wednesday, September 9th. Jefferies Financial Group reiterated a "buy" rating on shares of Haleon in a research report on Wednesday. Finally, Zacks Research raised shares of Haleon from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th.

Institutional Investors Weigh In On Haleon

Several institutional investors have recently made changes to their positions in HLN. QRG Capital Management Inc. raised its stake in shares of Haleon by 1.1% during the 2nd quarter. QRG Capital Management Inc. now owns 383,552 shares of the company's stock worth $3,579,000 after buying an additional 4,035 shares during the last quarter. Altar Rock LLC acquired a new stake in Haleon in the 2nd quarter valued at about $132,000. WINTON GROUP Ltd purchased a new position in Haleon during the 2nd quarter valued at about $494,000. Engineers Gate Manager LP purchased a new position in Haleon during the 2nd quarter valued at about $1,869,000. Finally, NorthRock Partners LLC raised its position in Haleon by 31.5% during the second quarter. NorthRock Partners LLC now owns 52,244 shares of the company's stock worth $487,000 after acquiring an additional 12,500 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Price Performance

Shares of NYSE HLN opened at $9.24 on Monday. The stock has a market cap of $40.66 billion, a P/E ratio of 23.71, a P/E/G ratio of 2.09 and a beta of 0.12. Haleon has a twelve month low of $8.65 and a twelve month high of $11.28. The stock has a 50 day moving average of $9.74 and a two-hundred day moving average of $9.59. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38.

Haleon Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, September 17th. Shareholders of record on Friday, August 14th were given a $0.0642 dividend. The ex-dividend date was Friday, August 14th. This is a negative change from Haleon's previous dividend of $0.1307. This represents a yield of 132.0%. Haleon's dividend payout ratio (DPR) is currently 30.77%.

About Haleon

Haleon plc NYSE: HLN is a global consumer healthcare company that develops, manufactures and markets products for everyday health and wellness needs. Its portfolio spans oral health, pain relief, respiratory health, vitamins and supplements, digestive health, and therapeutic skin care.

Haleon's well-known brands include Sensodyne, Polident, parodontax, Voltaren, Panadol, Advil, Centrum, Emergen-C, Theraflu, Otrivin, Calpol, ChapStick and Excedrin. The company sells its products through pharmacies, supermarkets, mass retailers, e-commerce platforms and other healthcare channels.

Haleon was formed through the demerger of GSK's consumer healthcare business and became an independent company in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.